Prostate Cancer - Results from #23780

GU Cancers Symposium 2013 - Utilization of cancer detection by U.S. prostate biospies (2005-2011), by Carl A. Olsson, MD, et al. - Session Highlights and Podcast February 20, 2013

GU Cancers Symposium 2013 - The ERα agonist, GTx-758, decreases bone turnover markers in men with advanced prostate cancer, by Evan Y. Yu, MD, et al. - Poster February 20, 2013

GU Cancers Symposium 2013 - Advanced prostate cancer patients treated with GTx-758 have a significantly lower rate of hot flashes, by Evan Y. Yu, MD, et al. - Poster February 20, 2013

GU Cancers Symposium 2013 - ARN-509 in men with high-risk non-metastatic castration-resistant prostate cancer, by Matthew R. Smith, MD, PhD - Session Highlights February 19, 2013

GU Cancers Symposium 2013 - ARN-509 in men with high-risk non-metastatic castration-resistant prostate cancer, by Matthew R. Smith, MD, PhD, et al. - Slide Presentation February 19, 2013

GU Cancers Symposium 2013 - GTx-758, an ERα agonist, reduces serum free testosterone and serum PSA in men with advanced prostate cancer, by Evan Y. Yu, MD, et al. - Poster February 19, 2013

Elderly prostate cancer patients: Patient information and shared decision making - Abstract February 19, 2013

Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications - Abstract February 19, 2013

Combining prostrate-specific antigen and Gleason score increases the diagnostic power of endorectal coil magnetic resonance imaging in prostate cancer pathological stage - Abstract February 19, 2013

Hybrid registration of prostate and seminal vesicles for image guided radiation therapy - Abstract February 19, 2013

Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer - Abstract February 19, 2013

Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy - Abstract February 19, 2013

GU Cancers Symposium 2013 - Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in patients with biochemically recurrent prostate cancer: Immune results, by Emmanuel S. Antonarakis, MD, et al February 19, 2013

Patient-health care provider communication among patients with newly diagnosed prostate cancer: Findings from a population-based survey - Abstract February 19, 2013

Place of residence and primary treatment of prostate cancer: Examining trends in rural and nonrural areas in Wisconsin - Abstract February 19, 2013

GU Cancers Symposium 2013 - Immune response to sipuleucel-T in patients with metastatic castrate-resistant prostate cancer (mCRPC): Phase 2 ProACT study, by Thomas A. Gardner, MD, et al. - Poster February 19, 2013

GU Cancers Symposium 2013 - Sipuleucel-T delayed time to first use of opioid analgesics in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer in the IMPACT trial, by Eric J. Small, MD, et al. - Poster February 19, 2013

Understanding and implementing immunotherapy for prostate cancer, by Charles G. Drake, MD, PhD of Johns Hopkins Kimmel Cancer Center February 19, 2013

GU Cancers Symposium 2013 - Real-world experience with sipuleucel-T in metastatic castration-resistant prostate cancer patients ≥ 80 years-old: Data from PROCEED, by A. Oliver Sartor, MD, et al. - Poster February 19, 2013

Agents that target androgen synthesis in castration-resistant prostate cancer - Abstract February 19, 2013

Page 1190 of 1434